T1	Participants 79 121	men receiving therapy for prostate cancer.
T2	Participants 611 672	men receiving androgen deprivation for their prostate cancer.
T3	Participants 1208 1342	195 men (65 subjects per arm) undergoing treatment for prostate cancer involving ADT in the cities of Perth and Brisbane in Australia.
